Form 4: Krystal Biotech CEO Krish Krishnan Sells Shares Under 10b5-1 Trading Plan

Krystal Biotech's CEO, Krish Krishnan S, and his spouse sold shares of the company's common stock on March 11, 2024, under pre-arranged 10b5-1 trading plans.

Summary

• On March 11, 2024, Krish S. Krishnan, the CEO of Krystal Biotech, Inc., sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan that started on September 11, 2023, and will end on September 11, 2024.
• The plan allows for the sale of up to 25,000 shares per quarter with a limit price of $100.00 per share.
• Krishnan sold 2,146 shares at a weighted average price of $167.9922, 2,254 shares at $168.8822, 5,109 shares at $170.3241, 8,002 shares at $170.9285, 2,816 shares at $172.0593, 3,359 shares at $173.0879 and 1,314 shares at $173.9959.
• Krishnan's spouse, Suma M. Krishnan, also sold shares under a separate 10b5-1 trading plan.
• Suma M. Krishnan sold 2,658 shares at a weighted average price of $168.1508, 1,646 shares at $168.9574, 8,040 shares at $170.4196, 5,469 shares at $171.0939, 2,800 shares at $172.2057, 3,587 shares at $173.2991 and 800 shares at $174.1313.
• Following these transactions, Krishnan directly owns 1,612,262 shares and indirectly owns 1,550,882 shares through his spouse, 90,000 shares through the Krishnan Spousal Trust, and 50,000 shares through the Krishnan Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating pre-planned stock sales by the CEO and his spouse. It doesn't inherently convey positive or negative sentiment, but rather reports factual transactions.

Future Outlook

The CEO and his spouse will continue to sell shares under their respective 10b5-1 trading plans until September 11, 2024, subject to the plans' limitations.

Industry Context

Sales by insiders are a common occurrence, and pre-planned sales under 10b5-1 plans are legal and allow insiders to diversify their holdings while avoiding accusations of trading on inside information.

Stakeholder Impact

• Shareholders may perceive the sales as a lack of confidence in the company, although the 10b5-1 plan mitigates this concern.
• The sales could create downward pressure on the stock price, although the impact is likely to be limited due to the pre-planned nature of the transactions.

Key Dates